Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an Anti-colony stimulating factor 1 receptor antibody
The use of CSF-1R-binding antibodies effectively addresses the challenge of treating cGVHD-related bronchiolitis obliterans syndrome by inhibiting CSF-1R function, showing clinical activity and safety in patients with advanced disease and multiple prior treatments.
WO2024238787A1PCT designated stage expired Publication Date: 2024-11-21SYNDAX PHARMACEUTICALS INC
Patent Information
- Application Number
- PCT/US2024/029683
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-17
- Filing Date
- 2024-05-16
- Publication Date
- 2024-11-21
Smart Images

Figure US2024029683_21112024_PF_FP_ABST
Abstract
The present disclosure provides methods of treating chronic graft-versus-host disease (cGVHD)-related bronchiolitis obliterans syndrome using an antibody that binds to colony stimulating factor 1 receptor (CSF-1R).
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Pharmaceutical formulation comprising antibodies which bind colony stimulating factor-1 receptor (CSF1R)
US10039826B2
Antibody affinity engineering by serial epitope-guided complementarity replacement
US20050008625A1
Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050037000A1
Synthetic antibody phage libraries
US20050079574A1
Antibodies against human CSF-1r and uses thereof
US20110165156A1
Cited By
Antibodies that bind to colony stimulating factor 1 receptor (CSF-1r) and uses thereof
WO2026147868A1
